{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T04:06:49Z","timestamp":1789531609343,"version":"build-2803163510"},"reference-count":30,"publisher":"Akademiai Kiado Zrt.","issue":"37","license":[{"start":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T00:00:00Z","timestamp":1789257600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.akjournals.com"],"crossmark-restriction":true},"short-container-title":["OH"],"published-print":{"date-parts":[[2026,9,13]]},"abstract":"A pszichedelikus kezel\u00e9sek alkalmaz\u00e1s\u00e1r\u00f3l sz\u00f3l\u00f3 szakirodalom az elm\u00falt \u00f6t \u00e9vben\n jelent\u0151sen b\u0151v\u00fclt. A hangulatzavarok, a ter\u00e1piarezisztens depressz\u00edv zavar \u00e9s a\n poszttraum\u00e1s stressz-zavar ter\u00fclet\u00e9n t\u00f6bb randomiz\u00e1lt-kontroll\u00e1lt vizsg\u00e1lat \u00e9s\n \u00f6sszegz\u0151 elemz\u00e9s jelent meg. A vizsg\u00e1lati m\u00f3dszertan azonban tov\u00e1bbra is\n alapvet\u0151 bizonytalans\u00e1gi forr\u00e1s, a klinikai bizony\u00edt\u00e9kok a ter\u00fclet\n n\u00e9pszer\u0171s\u00e9g\u00e9nek ellen\u00e9re szeg\u00e9nyesek. A pszilocibin alkalmaz\u00e1sa major depressz\u00edv\n zavarban k\u00f6vetkezetes \u00e9s nagym\u00e9rt\u00e9k\u0171 javul\u00e1ssal j\u00e1r, \u00e1m a legszigor\u00fabb\n vizsg\u00e1latokban a primer v\u00e9gpont nem mindig \u00e9ri el a statisztikai\n szignifikanci\u00e1t. Ugyanakkor egy szintetikus pszilocibin (COMP360) k\u00e9t\n 2025\u20132026-os, 3. f\u00e1zis\u00fa vizsg\u00e1lat\u00e1ban is teljes\u00edtette a primer v\u00e9gpontot. Az\n MDMA (metil\u00e9ndioxi-metamfetamin; \u201eecstasy\u201d) seg\u00edts\u00e9g\u00e9vel t\u00e1mogatott\n pszichoter\u00e1pia poszttraum\u00e1s stressz-zavarban rendelkezik a legmeggy\u0151z\u0151bb 3.\n f\u00e1zis\u00fa vizsg\u00e1lati anyaggal, az amerikai gy\u00f3gyszerhat\u00f3s\u00e1g azonban 2024-ben etikai\n agg\u00e1lyok miatt nem hagyta j\u00f3v\u00e1 a k\u00e9sz\u00edtm\u00e9nyt. Az LSD-nek (lizergsav-dietilamid)\n \u00e9s az ayahuasc\u00e1nak a depressz\u00edv t\u00fcnetekre \u00e9s szorong\u00e1sra gyakorolt hat\u00e1s\u00e1val\n kapcsolatos bizony\u00edt\u00e9kok l\u00e9nyegesen gyeng\u00e9bbek. A pszichedelikumok ter\u00e1pi\u00e1s\n haszn\u00e1lata ma m\u00e1r nem tekinthet\u0151 puszt\u00e1n elm\u00e9leti k\u00e9rd\u00e9snek vagy egy szubkult\u00fara\n mozgalm\u00e1nak: a klinikai hat\u00e1s k\u00f6vetkezetes, t\u00f6bb vizsg\u00e1latban pedig kifejezetten\n er\u0151s. A klinikai bizonyoss\u00e1g szintje azonban t\u00f6bb indik\u00e1ci\u00f3ban is alacsony vagy\n nagyon alacsony marad. Ennek f\u0151 okai a vak\u00edt\u00e1s gyakorlati felold\u00e1sa, a kis\n esetsz\u00e1mok, a vizsg\u00e1latok elt\u00e9r\u0151 jellege \u00e9s a hossz\u00fa t\u00e1v\u00fa biztons\u00e1gi adatok\n hi\u00e1nya. A pszilocibin \u00e9s a klasszikus pszichedelikumok egyel\u0151re k\u00eds\u00e9rleti\n kezel\u00e9snek tekinthet\u0151k. Az MDMA eset\u00e9ben a 3. f\u00e1zis\u00fa eredm\u00e9nyek \u00edg\u00e9retesek, de a\n hat\u00f3s\u00e1gi j\u00f3v\u00e1hagy\u00e1shoz nem bizonyultak elegend\u0151nek. Orv Hetil. 2026; 167(37):\n 1461\u20131467.<\/jats:p>","DOI":"10.1556\/650.2026.33665","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T03:24:09Z","timestamp":1789529049000},"page":"1461-1467","update-policy":"https:\/\/doi.org\/10.1556\/policypage.crossmark.crossref.2","source":"Crossref","is-referenced-by-count":0,"title":["Pszichedelikumok haszn\u00e1lata a pszichi\u00e1tri\u00e1ban"],"prefix":"10.1556","volume":"167","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7638-1741","authenticated-orcid":true,"given":"Szabolcs","family":"K\u00e9ri","sequence":"first","affiliation":[{"name":"Szegedi Tudom\u00e1nyegyetem, Szent-Gy\u00f6rgyi Albert Orvostudom\u00e1nyi Kar, \u00c9lettani Int\u00e9zet Szeged, D\u00f3m t\u00e9r 10., 6724 Magyarorsz\u00e1g"},{"name":"Tokaj-Hegyalja Egyetem, Szt\u00e1rai Int\u00e9zet S\u00e1rospatak Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"425","reference":[{"key":"R1","doi-asserted-by":"crossref","unstructured":"Torzsa P, Szeifert L, Dunai K, et al. Diagnosis and therapy of\n depression in family practice. [A depresszi\u00f3 diagnosztik\u00e1ja \u00e9s kezel\u00e9se a\n csal\u00e1dorvosi gyakorlatban.] Orv Hetil. 2009; 150: 1684-1693. [Hungarian]\n https:\/\/doi.org\/10.1556\/oh.2009.28675","DOI":"10.1556\/oh.2009.28675"},{"key":"R2","doi-asserted-by":"crossref","unstructured":"Fodor KE, Bitter I. Psychological interventions following trauma to\n prevent posttraumatic stress disorder. A systematic review of the literature.\n [Pszichol\u00f3giai intervenci\u00f3k traumatikus esem\u00e9nyek ut\u00e1n a poszttraum\u00e1s stressz\n zavar megel\u0151z\u00e9s\u00e9re. Szisztematikus irodalmi \u00e1ttekint\u00e9s.] Orv Hetil. 2015; 156:\n 1321-1334. [Hungarian]\n https:\/\/doi.org\/10.1556\/650.2015.30231","DOI":"10.1556\/650.2015.30231"},{"key":"R3","doi-asserted-by":"crossref","unstructured":"Osv\u00e1th P, Moln\u00e1r Cs, Lovig Cs, et al. Assessment of acute suicide\n risk. Opportunities for comprehensive risk evaluation in clinical practice. [Az\n akut szuicid vesz\u00e9ly \u00e9rt\u00e9kel\u00e9se. A komplex rizik\u00f3becsl\u00e9s lehet\u0151s\u00e9gei a klinikai\n gyakorlatban.] Orv Hetil. 2025; 166: 146-153. [Hungarian]\n https:\/\/doi.org\/10.1556\/650.2025.33211","DOI":"10.1556\/650.2025.33211"},{"key":"R4","doi-asserted-by":"crossref","unstructured":"Vollenweider FX, Preller KH. Psychedelic drugs: neurobiology and\n potential for treatment of psychiatric disorders. Nat Rev Neurosci. 2020; 21:\n 611-624. https:\/\/doi.org\/10.1038\/s41583-020-0367-2","DOI":"10.1038\/s41583-020-0367-2"},{"key":"R5","doi-asserted-by":"crossref","unstructured":"Muthukumaraswamy SD, Forsyth A, Lumley T. Blinding and expectancy\n confounds in psychedelic randomized controlled trials. Expert Rev Clin\n Pharmacol. 2021; 14: 1133-1152.\n https:\/\/doi.org\/10.1080\/17512433.2021.1933434","DOI":"10.1080\/17512433.2021.1933434"},{"key":"R6","unstructured":"U.S. Food and Drug Administration. Psychedelic drugs: considerations\n for clinical investigations. Guidance for Industry, 2023."},{"key":"R7","doi-asserted-by":"crossref","unstructured":"Daws RE, Timmermann C, Giribaldi B, et al. Increased global\n integration in the brain after psilocybin therapy for depression. Nat Med. 2022;\n 28: 844-851.\n https:\/\/doi.org\/10.1038\/s41591-022-01744-z","DOI":"10.1038\/s41591-022-01744-z"},{"key":"R8","doi-asserted-by":"crossref","unstructured":"Raison CL, Sanacora G, Woolley J, et al. Single-dose psilocybin\n treatment for major depressive disorder: a randomized clinical trial. JAMA 2023;\n 330: 843-853.\n https:\/\/doi.org\/10.1001\/jama.2023.14530","DOI":"10.1001\/jama.2023.14530"},{"key":"R9","doi-asserted-by":"crossref","unstructured":"Davis AK, Barrett FS, May DG, et al. Effects of psilocybin-assisted\n therapy on major depressive disorder: a randomized clinical trial. JAMA\n Psychiatry 2021; 78: 481-489.\n https:\/\/doi.org\/10.1001\/jamapsychiatry.2020.3285","DOI":"10.1001\/jamapsychiatry.2020.3285"},{"key":"R10","doi-asserted-by":"crossref","unstructured":"Gukasyan N, Davis AK, Barrett FS, et al. Efficacy and safety of\n psilocybin-assisted treatment for major depressive disorder: prospective\n 12-month follow-up. J Psychopharmacol. 2022; 36: 151-158.\n https:\/\/doi.org\/10.1177\/02698811211073759","DOI":"10.1177\/02698811211073759"},{"key":"R11","doi-asserted-by":"crossref","unstructured":"Carhart-Harris R, Giribaldi B, Watts R, et al. Trial of psilocybin\n versus escitalopram for depression. N Engl J Med. 2021; 384: 1402-1411.\n https:\/\/doi.org\/10.1056\/NEJMoa2032994","DOI":"10.1056\/NEJMoa2032994"},{"key":"R12","doi-asserted-by":"crossref","unstructured":"Goodwin GM, Aaronson ST, Alvarez O, et al. Single-dose psilocybin\n for a treatment-resistant episode of major depression. N Engl J Med. 2022; 387:\n 1637-1648. https:\/\/doi.org\/10.1056\/NEJMoa2206443","DOI":"10.1056\/NEJMoa2206443"},{"key":"R13","doi-asserted-by":"crossref","unstructured":"Mertens LJ, Koslowski M, Betzler F, et al. Efficacy and safety of\n psilocybin in treatment-resistant major depression: the EPISODE randomized\n clinical trial. JAMA Psychiatry 2026; 83: 448-460.\n https:\/\/doi.org\/10.1001\/jamapsychiatry.2026.0132","DOI":"10.1001\/jamapsychiatry.2026.0132"},{"key":"R14","unstructured":"Compass Pathways. Successfully achieves primary endpoint in first\n phase 3 trial evaluating COMP360 psilocybin for treatment-resistant depression.\n Available from:\n https:\/\/ir.compasspathways.com\/News--Events-\/news\/news-details\/2025\/Compass-Pathways-Successfully-Achieves-Primary-Endpoint-in-First-Phase-3-Trial-Evaluating-COMP360-Psilocybin-for-Treatment-Resistant-Depression\/default.aspx\n [accessed: 02 June, 2026]."},{"key":"R15","unstructured":"Compass Pathways. Successfully achieves primary endpoint in second\n phase 3 trial evaluating COMP360 psilocybin for treatment-resistant depression.\n Available from:\n https:\/\/ir.compasspathways.com\/News--Events-\/news\/newsdetails\/2026\/Compass-Pathways-Successfully-Achieves-Primary-Endpoint-in-Second-Phase-3-Trial-Evaluating-COMP360-Psilocybin-for-Treatment-Resistant-Depression\/default.aspx\n [accessed: 02 June, 2026]."},{"key":"R16","doi-asserted-by":"crossref","unstructured":"S. Parker Singleton, Sevchik BL, Lahey A, et al. A living systematic\n review, meta-analysis and open-data resource of randomized controlled trials of\n psilocybin treatment for symptoms of depression. Nature Mental Health 2026;\n 1-11. Doi: 10.1038\/s44220-026-00630-8.\n https:\/\/doi.org\/10.1038\/s44220-026-00630-8","DOI":"10.1038\/s44220-026-00630-8"},{"key":"R17","doi-asserted-by":"crossref","unstructured":"Haikazian S, Chen-Li DC, Johnson DE, et al. Psilocybin-assisted\n therapy for depression: a systematic review and meta-analysis. Psychiatry Res.\n 2023; 329: 115531.\n https:\/\/doi.org\/10.1016\/j.psychres.2023.115531","DOI":"10.1016\/j.psychres.2023.115531"},{"key":"R18","doi-asserted-by":"crossref","unstructured":"Dominiak M, G\u0119dek A, Modrzejewski S, et al. Efficacy and safety of\n psychedelics in mental disorder cases: an umbrella review of meta-analyses of\n randomized controlled trials. J Clin Med. 2026; 15: 253.\n https:\/\/doi.org\/10.3390\/jcm15010253","DOI":"10.3390\/jcm15010253"},{"key":"R19","doi-asserted-by":"crossref","unstructured":"Sloshower J, Skosnik PD, Safi-Aghdam H, et al. Psilocybin-assisted\n therapy for major depressive disorder: an exploratory placebo-controlled,\n fixed-order trial. J Psychopharmacol. 2023; 37: 698-706.\n https:\/\/doi.org\/10.1177\/02698811231154852","DOI":"10.1177\/02698811231154852"},{"key":"R20","doi-asserted-by":"crossref","unstructured":"Dutcher EG, Krystal AD. Treatment expectancies and psilocybin vs\n escitalopram for depression. JAMA Psychiatry 2025; 82: 321-322.\n https:\/\/doi.org\/10.1001\/jamapsychiatry.2024.4387","DOI":"10.1001\/jamapsychiatry.2024.4387"},{"key":"R21","doi-asserted-by":"crossref","unstructured":"Williams ZJ, Barnett H, Szigeti B. Psychedelic therapy vs\n antidepressants for the treatment of depression under equal unblinding\n conditions: a systematic review and meta-analysis. JAMA Psychiatry 2026; 83:\n 461-468.\n https:\/\/doi.org\/10.1001\/jamapsychiatry.2025.4809","DOI":"10.1001\/jamapsychiatry.2025.4809"},{"key":"R22","doi-asserted-by":"crossref","unstructured":"Bogenschutz MP, Ross S, Bhatt S, et al. Percentage of heavy drinking\n days following psilocybin-assisted psychotherapy vs placebo in the treatment of\n adult patients with alcohol use disorder: a randomized clinical trial. JAMA\n Psychiatry 2022; 79: 953-962.\n https:\/\/doi.org\/10.1001\/jamapsychiatry.2022.2096","DOI":"10.1001\/jamapsychiatry.2022.2096"},{"key":"R23","doi-asserted-by":"crossref","unstructured":"Mitchell JM, Bogenschutz M, Lilienstein A, et al. MDMA-assisted\n therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3\n study. Nat Med. 2021; 27: 1025-1033.\n https:\/\/doi.org\/10.1038\/s41591-021-01336-3","DOI":"10.1038\/s41591-021-01336-3"},{"key":"R24","doi-asserted-by":"crossref","unstructured":"Mitchell JM, Ot\u2019alora GM, van der Kolk B, et al. MDMA-assisted\n therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3\n trial. Nat Med. 2023; 29: 2473-2480.\n https:\/\/doi.org\/10.1038\/s41591-023-02565-4","DOI":"10.1038\/s41591-023-02565-4"},{"key":"R25","unstructured":"Reuters. US FDA declines to approve first MDMA-based PTSD treatment.\n Available from:\n https:\/\/www.reuters.com\/business\/healthcare-pharmaceuticals\/us-fda-declines-approve-first-mdma-based-ptsd-treatment-2024-08-09\/\n [accessed: 02 June, 2026]."},{"key":"R26","unstructured":"Halpern L, Hippensteele A. MDMA rejected. The story of a study\n participant entrenched ethical violations. Available from:\n https:\/\/www.pharmacytimes.com\/view\/mdma-rejected-the-story-of-a-study-participant-entrenched-in-ethical-violations-and-a-data-breach\n [accessed: 02 June, 2026]."},{"key":"R27","doi-asserted-by":"crossref","unstructured":"Ko K, Kopra EI, Cleare AJ, et al. Psychedelic therapy for depressive\n symptoms: a systematic review and meta-analysis. J Affect Disord. 2023; 322:\n 194-204. https:\/\/doi.org\/10.1016\/j.jad.2022.09.168","DOI":"10.1016\/j.jad.2022.09.168"},{"key":"R28","doi-asserted-by":"crossref","unstructured":"Frecska E, Bokor P, Winkelman M. The therapeutic potentials of\n ayahuasca: possible effects against various diseases of civilization. Front\n Pharmacol. 2016; 7: 35.\n https:\/\/doi.org\/10.3389\/fphar.2016.00035","DOI":"10.3389\/fphar.2016.00035"},{"key":"R29","doi-asserted-by":"crossref","unstructured":"Breeksema JJ, Kuin BW, Kamphuis J, et al. Adverse events in clinical\n treatments with serotonergic psychedelics and MDMA: a mixed-methods systematic\n review. J Psychopharmacol. 2022; 36: 1100-1117.\n https:\/\/doi.org\/10.1177\/02698811221116926","DOI":"10.1177\/02698811221116926"},{"key":"R30","doi-asserted-by":"crossref","unstructured":"Joga R, Yerram S, Patnam JD, et al. Unraveling the policies,\n legislations, and regulations of psychedelics in Australia, Canada, Netherlands,\n New Zealand, and India. Health Policy. 2025; 161: 105392.\n https:\/\/doi.org\/10.1016\/j.healthpol.2025.105392","DOI":"10.1016\/j.healthpol.2025.105392"}],"container-title":["Orvosi Hetilap"],"original-title":[],"link":[{"URL":"https:\/\/www.akjournals.com\/view\/journals\/650\/167\/37\/article-p1461.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.akjournals.com\/downloadpdf\/journals\/650\/167\/37\/article-p1461.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/www.akjournals.com\/downloadpdf\/journals\/650\/167\/37\/article-p1461.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T03:24:35Z","timestamp":1789529075000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.akjournals.com\/view\/journals\/650\/167\/37\/article-p1461.xml"}},"subtitle":["Mit mutatnak a klinikai bizony\u00edt\u00e9kok?"],"short-title":[],"issued":{"date-parts":[[2026,9,13]]},"references-count":30,"journal-issue":{"issue":"37"},"URL":"https:\/\/doi.org\/10.1556\/650.2026.33665","relation":{},"ISSN":["0030-6002","1788-6120"],"issn-type":[{"value":"0030-6002","type":"print"},{"value":"1788-6120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,13]]}}}